Lifeloc Technologies Reports 10% Revenue Growth in Q2 2026, Reduces Net Losses

Lifeloc Technologies, Inc. reported its financial results for the second quarter and first half of 2026, showing a notable improvement in revenue and a reduction in net losses compared to the same periods in 2025. For the three months ended June 30, 2026, total revenues reached $2.44 million, an increase of 10% from $2.22 million in the prior year. Product sales specifically rose by 11% to $2.43 million, driven by larger orders and improved customer funding availability. The company’s gross profit for the quarter was $1.09 million, reflecting an 18% increase from $924,599 in the previous year, with a gross profit margin improvement to 45% from 42%.

In the first half of 2026, Lifeloc's total revenues increased by 5% to $4.74 million, compared to $4.50 million in the same period of 2025. Product sales contributed $4.72 million, up 6% year-over-year. The gross profit for the six months was $2.08 million, a 13% increase from $1.83 million in 2025, with the gross profit margin rising to 44% from 41%. Despite these gains, the company reported a net loss of $287,043 for the first half of 2026, a significant reduction from the $686,325 loss recorded in the same period last year.

Operationally, Lifeloc has focused on maintaining cost control while investing in product development, particularly the SpinDetect™ platform for drug detection, which is expected to launch commercially in early 2027. Research and development expenses for the second quarter were $560,281, down 10% from the previous year, indicating a strategic shift in resource allocation. The company also reported a decrease in sales and marketing expenses, which fell by 6% to $320,968, as part of broader cost-reduction efforts.

As of June 30, 2026, Lifeloc's total assets stood at $7.08 million, up from $6.69 million at the end of 2025, with cash and cash equivalents increasing to $908,208. Current liabilities also rose to $1.10 million from $836,870, primarily due to increased accounts payable and term loans. The company’s stockholders’ equity decreased to $3.82 million from $4.10 million, reflecting the accumulated deficit which grew to $2.12 million.

Looking ahead, Lifeloc anticipates continued revenue growth driven by an expanding customer base and the introduction of new products. However, the company acknowledges the potential for ongoing operating losses as it invests in the commercialization of SpinDetect™. Management remains cautious about the impact of inflation on costs and the unpredictability of customer orders, emphasizing the need for careful financial management and potential additional capital to support operations if necessary.